The applications of intravenous opioids and multimodal analgesia in cancer pain management
-
摘要: 难治性癌性疼痛是全球肿瘤和疼痛医师所面临的治疗难题。虽然较多癌痛患者在疾病早期能获益于口服镇痛药物，但是对于疾病晚期和已出现难治性癌痛的患者，单纯的阿片类药物口服治疗效果较差，而此时将阿片类药物的给药途径更换为静脉仍然是最常使用的快速镇痛方法。目前，随着阿片类药物经静脉患者自控镇痛（patient controlled intravenous analgesia，PCIA）的临床实践不断增加，对该方式的适应证、药物选择、滴定等问题均有了更为深入的探讨。此外，在多模式镇痛的快速发展中，癌痛治疗的个体化措施有了更广阔的延伸空间。本文将对上述问题分别进行综述，旨在对难治性癌痛治疗方案的优化提供参考。Abstract: The management of refractory cancer pain remains a challenge for oncologists and pain physicians worldwide. Although a large number of patients with cancer pain benefit from oral analgesics in the early stages, single oral opioids tend to be less effective in patients with the advanced disease and refractory cancer pain; for this, intravenous opioid administration is the most commonly used rapid analgesic option. Currently, the increasing clinical use of opioid-patient controlled intravenous analgesia (PCIA) has generated extensive discussion on its indications, drug selection, titration, and other related topics. In addition, with the rapid development of multimodal analgesia, the individualized measures for cancer pain management show a broader exploratory scope. We will review the above topics in this article with the hope of providing some references for treatment optimization in refractory cancer pain management.
-
Key words:
- cancer pain /
- opioid rotation /
- PCIA /
- rapid titration /
- multimodal analgesia
-
表 1 阿片类药物换算表
表 2 口服吗啡与静脉阿片类药物换算表
-
[1] Allemani C, Weir HK, Carreira H, et al. Concord working group global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (concord-2)[J]. Lancet, 2015, 385(9972):977-1010. doi: 10.1016/S0140-6736(14)62038-9 [2] Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer[J]. Cancer, 2014, 120(9):1290-1314. doi: 10.1002/cncr.28509 [3] Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (2008-2030): a population-based study [J]. Lancet Oncol, 2012, 13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5 [4] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):e359-e386. doi: 10.1002/ijc.29210 [5] Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013 [J]. JAMA Oncol, 2015, 1(4):505-527. doi: 10.1001/jamaoncol.2015.0735 [6] Harris JT, Suresh KK, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain[J]. Palliat Med, 2003, 17(3):248-256. doi: 10.1191/0269216303pm695oa [7] Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC[J]. Lancet Oncol, 2012, (13):e58-e68. http://www.ncbi.nlm.nih.gov/pubmed/22300860 [8] Dy SM, Asch SM, Naeim A, et al. Evidence-based standards for cancer pain management[J]. J Clin Oncol, 2008, 26(23):3879-3885. doi: 10.1200/JCO.2007.15.9517 [9] Koyyalagunta D, Bruera E, Solanki DR, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain[J]. Pain Physician, 2012, 15(3 Suppl):es39-es58. http://europepmc.org/abstract/MED/22786461 [10] World health organization. Cancer pain relief[M]. Second edition. Geneva, Switzerland: World Health Organization, 1996:1-69. [11] Ahlbeck K. Opioids: a two-faced Janus[J]. Curr Med Res Opin, 2011, 27 (2):439-448. doi: 10.1185/03007995.2010.545379 [12] Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration[J]. Cancer, 1995, 76(7):1283-1293. doi: 10.1002/(ISSN)1097-0142 [13] Hanks GW, Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations[J]. Br J Cancer, 2001, 84(5): 587-593. doi: 10.1054/bjoc.2001.1680 [14] Mercadante S. Intravenous morphine for management of cancer pain [J]. Lancet Oncol, 2010, 11(5):484-489. doi: 10.1016/S1470-2045(09)70350-X [15] Hagen NA, Elwood T, Ernst S. Cancer pain emergencies: a protocol for management[J]. J Pain Symptom Manage, 1997, 14(1):45-50. http://europepmc.org/abstract/MED/9223842 [16] Snow H. Opium and cocaine in the treatment of cancerous disease[J]. Br Med J, 1996, 2(1864):718-719 http://www.jstor.org/stable/20237245 [17] Yang Y, Li Y, Huang XE, et al. Exploration of cancer pain treatment by morphine infusion through an embedded device[J]. Asian Pac J Cancer Prev, 2011, 12(11):3151-3152. https://www.researchgate.net/publication/221680955_Exploration_of_cancer_pain_treatment_by_morphine_infusion_through_an_embedded_device [18] Muller W, Hallermann S, Swandulla D. Opioidergic modulation of voltage-activated κ + currents in magnocellular neurons of the supraoptic nucleus in rat[J]. J Neurophysiol, 1999, 81(4):1617-1625. doi: 10.1152/jn.1999.81.4.1617 [19] Prado WA. Involvement of calcium in pain and antinociception[J]. Braz J Med Biol Res, 2001, 34(4):449-461. doi: 10.1590/S0100-879X2001000400003 [20] Inturrisi CE. Clinical pharmacology of opioids for pain[J]. Clin J Pain, 2002, 18(4 Suppl):S3-S13. http://europepmc.org/abstract/MED/12479250 [21] Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs[J]. Anesthesiology, 1992, 76(3):334-341. doi: 10.1097/00000542-199203000-00003 [22] Monk JP, Beresford R, Ward A. Sufentanil, a review of its pharmacological properties and therapeutic use[J]. Drugs, 1988, 36(3):286-313. doi: 10.2165/00003495-198836030-00003 [23] 楼尉, 陈骏萍.舒芬太尼自控静脉镇痛与吗啡硬膜外镇痛在爆发性癌痛治疗中的比较[J].中国疼痛医学杂志, 2011, 17(12):762-763. doi: 10.3969/j.issn.1006-9852.2011.12.018 [24] Quigley C. Hydromorphone for acute and chronic pain[J]. Cochrane Database Syst Rev, 2002, (1):CD003447. doi: 10.1002/14651858.CD003447/full [25] Coda B, Tanaka A, Jacobson R C, et al. Hydromorphone analgesia after intravenous bolus administration[J]. Pain, 1997, 71(1):41-48. doi: 10.1016/S0304-3959(97)03336-8 [26] Oldenmenger WH, Lieverse PJ, Janssen PJ, et al. Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids[J]. Support Care Cancer, 2012, 20(8): 1639-1647. doi: 10.1007/s00520-011-1254-1 [27] Bao YJ, Hou W, Kong XY, et al. Hydromorphone for cancer pain[J]. Cochrane Database Syst Rev, 2016, (10):CD011108. http://www.ncbi.nlm.nih.gov/pubmed/27727452 [28] Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review[J]. Palliat Med, 2011, 25(5):471-477. doi: 10.1177/0269216310387962 [29] Liu R, Huang XP, Yeliseev A, et al. Novel molecular targets of dezocine and their clinical implications[J]. Anesthesiology, 2014, 120(3):714-723. doi: 10.1097/ALN.0000000000000076 [30] Abdelhamid EE, Sultana M, Portoghese PS, et al. Selective blockage of delta opioid receptors the development of morphine tolerance and dependence in mice[J]. Pharmacol Exp Ther, 1991, (258):299-303. http://www.ncbi.nlm.nih.gov/pubmed/1649297?dopt=Abstract [31] Vogelsang J, Hayes SR. Butorphanol tartrate (stadol): a review[J]. J Post Anesth Nurs, 1991, 6(2):129-135. http://www.ncbi.nlm.nih.gov/pubmed/1848891 [32] Wu TT, Wang ZG, Ou WL, et al. Intravenous flurbiprofen axetil enhances analgesic effect of opioids in patients with refractory cancer pain by increasing plasma beta-endorphin[J]. Asian Pac J Cancer Prev, 2014, 15(24):10855-10860. http://europepmc.org/abstract/med/25605189 [33] Hao J, Wang K, Shao Y, et al. Intravenous flurbiprofen axetil to relieve cancer-related multiple breakthrough pain: a clinical study[J]. J Palliat Med, 2013, 16(2):190-192. doi: 10.1089/jpm.2012.0353 [34] Roszkowski MT, Swift JQ, Hargreaves KM. Effect of NSAID administration on tissue levels of immunoreactive prostaglandin E2, leukotriene B4, and (S)-flurbiprofen following extraction of impacted third molars[J]. Pain, 1997, 73(3):339-345. doi: 10.1016/S0304-3959(97)00120-6 [35] Ochroch EA, Mardini IA, Gottschalk A. What is the role of NSAIDs in preemptive analgesia[J]? Drugs, 2003, 63(24):2709-2723. doi: 10.2165/00003495-200363240-00002 [36] Su C, Su Y, Chou CW, et al. Intravenous flurbiprofen for post-thymectomy pain relief in patients with myasthenia gravis[J]. J Cardiothorac Surg, 2012, (7):98. http://europepmc.org/articles/pmc3493291/ [37] Armstrong P, Wilkinson P, Mccorry NK. Use of parecoxib by continuous subcutaneous infusion for cancer pain in a hospice population[J]. BMJ Support Palliat Care, 2017. [Epub ahead of print] http://europepmc.org/abstract/MED/28864447 [38] Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults[J]. Ann Pharmacother, 2009, (43):2064-2074. doi: 10.1345/aph.1M310 [39] Gerlach AT, Dasta JF. Dexmedetomidine: an updated review[J]. Ann Pharmacother, 2007, 41(2):245-252. doi: 10.1345/aph.1H314 [40] Haselman MA. Dexmedetomidine: a useful adjunct to consider in some high-risk situations[J]. AANA J, 2008, 76(5):335-339. http://europepmc.org/abstract/MED/18947160 [41] Blaudszun G, Lysakowski C, Elia N, et al. Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials[J]. Anesthesiology, 2012, 116(6):1312-1322. doi: 10.1097/ALN.0b013e31825681cb [42] Belgrade M, Hall S. Dexmedetomidine infusion for the management of opioid-induced hyperalgesia[J]. Pain Med, 2010, 11(12):1819-1826. doi: 10.1111/j.1526-4637.2010.00973.x [43] Day MA, Rich MA, Thorn BE, et al. A placebo-controlled trial of midazolam as an adjunct to morphine patient-controlled analgesia after spinal surgery[J]. J Clin Anesth, 2014, 26(4):300-308. doi: 10.1016/j.jclinane.2013.12.011 [44] Villars P, Dodd M, West C, et al. Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain[J]. J Pain Symptom Manage, 2007, 33(1):67-77. doi: 10.1016/j.jpainsymman.2006.07.011 [45] Moore RA, Mcquay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids[J]. Arthritis Res Ther, 2005, 7(5):r1046-r1051. doi: 10.1186/ar1782 [46] Herndon CM, Jackson KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care[J]. Pharmacotherapy, 2002, 22(2):240-250. doi: 10.1592/phco.22.3.240.33552 [47] Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies[J]. Drugs, 2003, 63(7):649-671. doi: 10.2165/00003495-200363070-00003 [48] Shukla VK, Turndorf H, Bansinath M. Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition[J]. Eur J Pharmacol, 1995, 292(3-4):293-299. https://www.sciencedirect.com/science/article/pii/0926691795900357 [49] Popper P, Cristobal R, Wackym PA. Expression and distribution of mu opioid receptors in the inner ear of the rat[J]. Neuroscience, 2004, 129 (1):225-233. doi: 10.1016/j.neuroscience.2004.08.008 [50] Rung GW, Claybon L, Hord A, et al. Intravenous ondansetron for postsurgical opioid-induced nausea and vomiting. S3A-255 Study Group[J]. Anesth Analg, 1997, 84(4):832-838. doi: 10.1213/00000539-199704000-00025 [51] Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options[J]. Pain Med, 2009, 10(4):654-662. doi: 10.1111/j.1526-4637.2009.00583.x [52] Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study [J]. Anesth Analg, 2005, (100):953-958. https://jhu.pure.elsevier.com/en/publications/the-effects-of-a-small-dose-naloxone-infusion-on-opioid-induced-s-3 [53] Abul-Husn NS, Sutak M, Milne B, et al. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu-and delta-opioid receptor antagonists[J]. Br J Pharmacol, 2007, 151(6):877-887. doi: 10.1038/sj.bjp.0707277 [54] Lin YS, Tsai R Y, Shen CH, et al. Ultra-low dose naloxone restores the antinocicepitve effect of morphine in PTX-treated rats: association of IL-10 upregulation in the spinal cord[J]. Life Sci, 2012, 91(5-6):213-220. doi: 10.1016/j.lfs.2012.07.005 [55] Movafegh A, Shoeibi G, Ansari M, et al. Naloxone infusion and posthysterectomy morphine consumption: a double-blind, placebo-controlled study[J]. Acta Anaesthesiol Scand, 2012, 56(10):1241-1249. doi: 10.1111/aas.2012.56.issue-10 [56] Wood DE. National comprehensive cancer network, NCCN clinical practice guidelines for adult cancer Pain[J]. Thora Surg Clin, 2014, 24 (2):185. [57] Zeng XH, Li JH, Wan XM, et al. NCCN national comprehensive cancer network. NCCN clinical practice guidelines for adult cancer pain[J]. Pharmaco Economics, 2014, (32):235-243. https://www.nccn.org/professionals/physician_gls/default.aspx [58] Laroche F, Rostaing S, Aubrun F, et al. Pain management in heroin and cocaine users[J]. Joint Bone Spine, 2012, 79(5):446-450. doi: 10.1016/j.jbspin.2012.01.007 [59] Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine[J]. Cancer, 1996, 78(4): 852-857. doi: 10.1002/(ISSN)1097-0142 [60] Pereira J, Lawlor P, Vigano A, et al. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing[J]. J Pain Symptom Manage, 2001, 22(2):672-687. doi: 10.1016/S0885-3924(01)00294-9 [61] Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: where is the evidence[J]? Pain Pract, 2010, 10(2):85-93. http://europepmc.org/abstract/MED/20070552 [62] Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table[J]. J Pain Symptom Manage, 2009, 38(3):426-439. doi: 10.1016/j.jpainsymman.2009.06.001 [63] Passik SD, Webster L. Opioid analgesics: does potency matter[J]? J Opioid Manag, 2014, 10(4):263-275. doi: 10.5055/jom.2014.021X [64] Engstrom PF, Benson AB 3rd, Cohen A, et al. National comprehensive cancer network. NCCN clinical practice guidelines for Adult Cancer Pain [J]. Oncol, 2014, 10(11 Suppl):140-175. [65] 王昆, 金毅.难治性癌痛专家共识(2017年版)[J].中国肿瘤临床, 2017, 44(16):787-793. http://html.rhhz.net/ZGZLLC/html/2017-16-1.htm [66] Candido KD, Kusper TM, Knezevic NN. New cancer pain treatment options[J]. Curr Pain Headache Rep, 2017, 21(2):12. doi: 10.1007/s11916-017-0613-0 [67] Syrjala KL, Jensen MP, Mendoza ME, et al. Psychological and behavioral approaches to cancer pain management[J]. J Clin Oncol, 2014, 32(16): 1703-1711. doi: 10.1200/JCO.2013.54.4825 -
点击查看大图
表(2)
计量
- 文章访问数: 51
- HTML全文浏览量: 33
- PDF下载量: 5
- 被引次数: 0
下载:
